1. A disproportionality analysis of CDK4/6 inhibitors in the FDA Adverse Event Reporting System (FAERS)
   Yuan Peng et al, 2024, Expert Opinion on Drug Safety CrossRef
2. The Cyclin-Dependent Kinase 4/6 Inhibitor Abemaciclib Is Tolerated Better than Palbociclib by Advanced Breast Cancer Patients with High Serum Albumin Levels
   Hitomi Nakatsukasa et al, 2022, Biological and Pharmaceutical Bulletin CrossRef
3. Safety in Japanese Advanced Breast Cancer Patients Who Received Abemaciclib in MONARCH 2 and MONARCH 3: Assessment of Treatment-Emergent Neutropenia, Diarrhea, and Increased Alanine Aminotransferase and Aspartate Aminotransferase Levels
   Norikazu Masuda et al, 2022, Cancer Management and Research CrossRef
4. Palbociclib
   , 2020, Reactions Weekly CrossRef